Geron Announces Conference Call to Discuss Third Quarter Financial Results and Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2011 on Thursday, November 3, 2011, after the closing of the equity market. David L. Greenwood, Geron’s President and Chief Financial Officer, and John Scarlett, M.D., Geron’s Chief Executive Officer, will host a conference call for analysts and investors on Friday, November 4, 2011 at 6:00 a.m. Pacific Time, 9:00 a.m. Eastern Time.

Participants can access the conference call live via telephone by dialing 800-706-7748 (U.S.); 617-614-3473 (international). The passcode is 53572623. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://www.media-server.com/m/p/2j4c3p37. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through December 5, 2011.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapies from differentiated human embryonic stem cells, with the first product in a Phase 1 clinical trial for spinal cord injury. For more information, visit www.geron.com.



CONTACT:

Geron Corporation
Anna Krassowska, Ph.D., Investor and Media Relations, 650-473-7765
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.